Emcure Pharmaceuticals Ltd
EMCUREEmcure Pharmaceuticals Ltd
EMCURE
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 8.33 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Emcure Pharmaceuticals is engaged in developing, manufacturing and marketing a range of pharmaceutical products across several therapeutic areas.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,274.01 | 4,911.74 | 5,130.86 | 5,067.35 | 5,918.86 | 6,031.72 | 6,715.24 | — | ||||||||
Raw Materials | 1,414.88 | 1,890.86 | 2,027.58 | 2,188.68 | 2,378.55 | 2,193.84 | 2,665.61 | — | ||||||||
| Power & Fuel Cost | 83.14 | 94.47 | 100.81 | 94.85 | 97.28 | 108.58 | 120.04 | |||||||||
| Employee Cost | 887.46 | 1,010.33 | 1,105.62 | 902.81 | 1,011.82 | 1,117.33 | 1,292.08 | |||||||||
| Selling & Administrative Expenses | 651.74 | 684.16 | 809.58 | 403.93 | 716.19 | 840.84 | 998.47 | |||||||||
| Operating & Other expenses | 542.55 | 411.47 | 404.50 | 420.10 | 321.63 | 550.19 | 362.26 | |||||||||
EBITDA | 694.24 | 820.45 | 682.77 | 1,056.98 | 1,393.39 | 1,220.94 | 1,276.78 | — | ||||||||
| Depreciation/Amortization | 228.05 | 267.17 | 320.83 | 249.99 | 244.86 | 260.12 | 312.41 | — | ||||||||
| PBIT | 466.19 | 553.28 | 361.94 | 806.99 | 1,148.53 | 960.82 | 964.37 | — | ||||||||
| Interest & Other Items | 175.73 | 222.66 | 256.60 | 154.94 | 175.98 | 213.61 | 237.15 | — | ||||||||
| PBT | 290.46 | 330.62 | 105.34 | 652.05 | 972.55 | 747.21 | 727.22 | — | ||||||||
| Taxes & Other Items | 115.37 | 135.55 | 21.73 | 233.44 | 310.35 | 215.20 | 229.04 | — | ||||||||
| Net Income | 175.09 | 195.07 | 83.61 | 418.61 | 662.20 | 532.01 | 498.18 | — | ||||||||
| EPS | 9.68 | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.52 | — | ||||||||
| DPS | 3.50 | 3.50 | 0.00 | 1.00 | 3.00 | 2.00 | — | — | ||||||||
| Payout ratio | 0.36 | 0.32 | 0.00 | 0.04 | 0.08 | 0.07 | 0.00 | — |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Emcure Pharmaceuticals Ltd | 52.22 | 8.33 | — |
| Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
| Cipla Ltd | 31.71 | 4.88 | 0.80% |
| Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare EMCURE with any stock or ETFShareholdings
Promoter Holdings Trend
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
No institutional holdings trend are available
Shareholding Pattern
Jul 2024
Shareholding History
Mutual Funds Holding Trend
No mutual funds holding trends are available
Top 5 Mutual Funds holding Emcure Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Nippon India Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4723% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months 0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 98/117 (+18) |
Aditya Birla Sun Life ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.2100% | Percentage of the fund’s portfolio invested in the stock 0.32% | Change in the portfolio weight of the stock over the last 3 months 0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 72/73 (+1) |
Mahindra Manulife Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.1883% | Percentage of the fund’s portfolio invested in the stock 0.97% | Change in the portfolio weight of the stock over the last 3 months 0.97% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/97 (+22) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Emcure Pharmaceuticals rose 10.48% to Rs 144.08 crore in the quarter ended June 2024 as against Rs 130.41 crore during the previous quarter ended June 2023. Sales rose 16.64% to Rs 1815.14 crore in the quarter ended June 2024 as against Rs 1556.16 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1815.141556.16 17 OPM %18.5319.00 - PBDT301.00258.52 16 PBT207.41191.34 8 NP144.08130.41 10 Powered by Capital Market - Live
Emcure Pharmaceuticals has received upgrade in credit ratings from CRISIL for bank facilities of Rs 2,475.43 crore of the company as under: Long term rating - CRISIL AA-/ Stable Short term rating - CRISIL A1+Powered by Capital Market - Live
Emcure Pharmaceuticals announced that CARE Ratings has upgraded the credit ratings assigned to bank facilities of the company as under: Long term bank facilities (Rs 557.50 crore) - CARE AA-; Stable Long term / short term bank facilities (Rs 1,286 crore) - CARE AA-; Stable/ CARE A1+ Short term bank facilities (Rs 114 crore) - CARE A1+Powered by Capital Market - Live
Emcure Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 6.45%, vs industry avg of 9.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 2.17% to 1.78%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 20.63%, vs industry avg of 15.17%